Loading clinical trials...
Loading clinical trials...
A Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial of Deferasirox in Patients With Myelodysplastic Syndromes (Low/Int-1 Risk) and Transfusional Iron Overload
Conditions
Interventions
Deferasirox
Placebo
Locations
71
United States
Pacific Cancer Medical Center, Inc. PAC Center
Anaheim, California, United States
Rocky Mountain Cancer Centers RMCC
Greenwood Village, Colorado, United States
Willis-Knighton Cancer Center Dept of Onc
Shreveport, Louisiana, United States
Henry Ford Hospital Henry Ford
Detroit, Michigan, United States
Midwest Cancer Care Physicians MMCC
Kansas City, Missouri, United States
Mercy Medical Research Institute SC
Manchester, Missouri, United States
Start Date
March 22, 2010
Primary Completion Date
February 27, 2018
Completion Date
February 27, 2018
Last Updated
November 23, 2020
NCT06303193
NCT06847867
NCT06439199
NCT07216443
NCT05588154
NCT06656494
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions